Skip to main content
Top
Published in: Diabetologia 6/2007

01-06-2007 | Research Letter

Modified end-stage renal disease risk score for Chinese type 2 diabetic patients—the Hong Kong Diabetes Registry

Authors: X. L. Yang, W. Y. So, A. P. S. Kong, C. S. Ho, C. W. K. Lam, M. H. L. Ng, R. R. Lyu, D. D. Yin, C. C. Chow, C. S. Cockram, P. C. Y. Tong, J. C. N. Chan

Published in: Diabetologia | Issue 6/2007

Login to get access

Excerpt

Ma et al. [1] recalibrated the Modification of Diet in Renal Disease (MDRD) equation for estimation of the GFR of Chinese individuals. It was reported that it is necessary for the GFR derived from the original MDRD equation to be multiplied by an adjusting coefficient of 1.233. This recalibration for Chinese individuals may have a significant effect on the end-stage renal disease (ESRD) risk score [2]. If a GFR of 15 ml min−1 1.73 m−2 is used to define ESRD, patients with values between 12.17 and 15.00 ml min−1 1.73 m−2 estimated by the original MDRD equation will no longer meet the definition of ESRD by the Chinese recalibrated MDRD (C-MDRD) equation. The aim of the present study was to examine the effect of the C-MDRD equation on the validity of the ESRD risk score for Chinese patients with type 2 diabetes mellitus [2]. …
Appendix
Available only for authorised users
Literature
1.
go back to reference Ma YC, Zuo L, Chen JH et al (2006) Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17:2937–2944PubMedCrossRef Ma YC, Zuo L, Chen JH et al (2006) Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17:2937–2944PubMedCrossRef
2.
go back to reference Yang XL, So WY, Kong AP et al (2006) End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry. Diabetologia 49:2299–2308PubMedCrossRef Yang XL, So WY, Kong AP et al (2006) End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry. Diabetologia 49:2299–2308PubMedCrossRef
3.
go back to reference Gooley TA, Leisenring W, Crowley J et al (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18:695–706PubMedCrossRef Gooley TA, Leisenring W, Crowley J et al (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18:695–706PubMedCrossRef
4.
go back to reference Chambless LE, Diao G (2006) Estimation of time-dependent area under the ROC curve for long-term risk prediction. Stat Med 25:3474–3486PubMedCrossRef Chambless LE, Diao G (2006) Estimation of time-dependent area under the ROC curve for long-term risk prediction. Stat Med 25:3474–3486PubMedCrossRef
Metadata
Title
Modified end-stage renal disease risk score for Chinese type 2 diabetic patients—the Hong Kong Diabetes Registry
Authors
X. L. Yang
W. Y. So
A. P. S. Kong
C. S. Ho
C. W. K. Lam
M. H. L. Ng
R. R. Lyu
D. D. Yin
C. C. Chow
C. S. Cockram
P. C. Y. Tong
J. C. N. Chan
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0639-7

Other articles of this Issue 6/2007

Diabetologia 6/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.